USA News Group News
Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, Jan. 22,
2025 /CNW/ -- USA
News Group News Commentary – Big developments are
expected this week at the 2025 ASCO Gastrointestinal Cancers
Symposium, running January 23-25 in
San Francisco. This year's event
is particularly critical as researchers highlight the alarming rise
in cancer rates among people under 50, with gastrointestinal
cancers leading the increase. Colorectal and pancreatic cancers,
two of the top three deadliest cancer types, remain significant
concerns as pancreatic cancer mortality continues to climb. Among
the innovators presenting at the symposium are Oncolytics
Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Agenus Inc.
(NASDAQ: AGEN), Guardant Health, Inc. (NASDAQ: GH), Xilio
Therapeutics, Inc. (NASDAQ: XLO), and RenovoRx, Inc.
(NASDAQ: RNXT).
The article continued: According to USD Analytics'
recently introduced study, the Global Pancreatic Cancer Treatment
Market is expected to soar in the upcoming years, growing at a 7.6%
CAGR. Analysts at Precedence Research project that the
global stomach cancer treatment market will grow at a 12.54%
CAGR to US17.6 billion by 2034.
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a
leading clinical-stage company specializing in immunotherapy for
oncology, today shared details about the data it will present at
the ASCO GI symposium. The presentations will highlight
pelareorep, an innovative immunotherapy that trains the immune
system to target cancer by turning "cold" tumors—typically
resistant to treatment—into "hot" tumors that respond better to
therapy.
In relapsed anal cancer, 4 out of 12 evaluable patients achieved
a partial response for a response rate of 33%, and one patient
achieved a remarkable complete response, meaning their cancer
became undetectable and remained so for over 15 months. To put this
into perspective, similar treatments typically achieve response
rates of only 10-24%. This underscores pelareorep's potential to
deliver life-changing results in some of the toughest-to-treat
cancers.
"In relapsed anal cancer, the efficacy signal that was initially
reported continues to outperform historical control trials with the
inclusion of additional patients," said Thomas Heineman, M.D., Ph.D., Chief Medical
Officer for Oncolytics Biotech. "Importantly, the complete
response we observed previously continued beyond the 12 months
initially reported. Together, these results point to a clinically
meaningful synergy between pelareorep and checkpoint inhibitors
like atezolizumab."
In pancreatic cancer, pelareorep has also demonstrated strong
potential to improve outcomes for patients with this aggressive
disease. The upcoming ASCO GI presentation will feature new
safety data showing that pelareorep can be combined with modified
FOLFIRINOX, another widely used chemotherapy regimen for patients
with pancreatic cancer.
"Our new safety data indicate its ability to also be combined
with modified FOLFIRINOX, thus expanding its potential to benefit
patients with metastatic pancreatic cancer," added Dr. Heineman.
"We will continue to provide updates on the safety and efficacy of
pelareorep-based combination therapy from these cohorts as they
become available."
This builds on prior results from the GOBLET study, where
pelareorep, combined with atezolizumab, gemcitabine, and
nab-paclitaxel, achieved a 62% objective response rate—more than
double historical averages of 25%. These findings were pivotal in
earning pelareorep FDA Fast Track designation in 2022,
highlighting its promise to fill the critical unmet need for more
effective pancreatic cancer therapies.
The ability to pair pelareorep with modified FOLFIRINOX
represents an important step forward in expanding treatment options
for metastatic pancreatic cancer. These results not only highlight
pelareorep's versatility but also its potential to enhance outcomes
across multiple standard-of-care therapies.
"I am quite pleased by these recent updates from the GOBLET
study as they continue to provide potential new treatment options
for patients in need of alternatives while maintaining a manageable
safety profile," said Dirk Arnold,
M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg, and
primary investigator of the GOBLET trial. "I've been especially
impressed with the ability of pelareorep-based therapies to work
across multiple challenging cancer indications and with multiple
standards of care, including chemotherapy and checkpoint
inhibitors, so I look forward to additional data readouts that can
help improve the treatment paradigm."
As Oncolytics Biotech advances its clinical programs and
prepares for pivotal studies, the growing body of evidence
continues to solidify pelareorep as a transformative therapeutic
option for patients in desperate need of effective treatments.
CONTINUED… Read this and more news for Oncolytics Biotech
at:
https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/
In other recent industry developments and happenings in the
market include:
Agenus Inc. (NASADAQ: AGEN), a leader in immuno-oncology,
recently announced it too will share five presentations at
ASCO GI's symposium featuring botensilimab (BOT, an
Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (BAL, an
anti-PD-1 antibody), and showcasing BOT/BAL's consistent activity
in microsatellite stable (MSS) colorectal cancer (CRC), which
accounts for over 80% of CRC cases and has limited treatment
options, as well as its efficacy in microsatellite instability-high
(MSI-H) CRC. Additionally, one presentation will feature BOT/BAL
and invariant natural killer T cells (iNKTs) in patients with
refractory gastric cancer.
"These presentations will highlight BOT/BAL's potential to
benefit patients across colorectal cancer treatment settings,
including the neoadjuvant, late-line, and first-line settings,"
said Dr. Garo Armen, Chairman and
CEO of Agenus. "We aim to transform outcomes at every stage
of disease and deliver renewed hope for patients worldwide."
ALX Oncology Holdings Inc. (NASDAQ: ALXO), a
clinical-stage biotechnology company advancing therapies that boost
the immune system to treat cancer and extend patients' lives, also
recently announced that updated results from its Phase 2 ASPEN-06
clinical trial were accepted for oral presentation at ASCO GI
2025.
ASPEN-06 is a global clinical
trial testing evorpacept, ALX Oncology's innovative
therapy designed to block the "don't eat me" signal used by cancer
cells to evade the immune system. The study is evaluating
evorpacept in combination with trastuzumab, CYRAMZA® (ramucirumab),
and paclitaxel (a combination known as TRP) compared to TRP alone
in patients with HER2-positive gastric or gastroesophageal junction
cancer who have previously received anti-HER2 treatments. This
approach aims to enhance the effectiveness of existing therapies
and improve outcomes for patients with this aggressive cancer
type.
Xilio Therapeutics, Inc. (NASDAQ: XLO),
a clinical-stage biotechnology company discovering and
developing tumor-activated immuno-oncology therapies for people
living with cancer, recently announced its plans to present
initial data from its ongoing Phase 2 trial for vilastobart
(XTX101), a tumor-activated, Fc-enhanced, high affinity binding
anti-CTLA-4, in combination with atezolizumab (Tecentriq®) in
patients with metastatic microsatellite stable colorectal cancer
(MSS CRC) at the ASCO GI Symposium. In addition, the company
also announced preliminary data from Phase 1 dose escalation for
XTX301, an investigational tumor-activated IL-12.
"We are encouraged by the early evidence of responses in
patients with cold tumors, including MSS colorectal cancer,
reported for the combination of vilastobart and atezolizumab
in Phase 1C dose escalation earlier this year, and we look forward
to sharing initial Phase 2 data for the combination in MSS CRC at
ASCO GI in January," said Katarina Luptakova, M.D., Chief Medical
Officer of Xilio. "In addition, the preliminary Phase 1 data
we reported today for XTX301, our tumor-activated IL-12, highlight
its promising clinical profile, including no dose-limiting
toxicities reported to date and consistent interferon gamma
signaling observed throughout treatment cycles."
RenovoRx, Inc. (NASDAQ: RNXT), a life sciences company
developing novel targeted oncology therapies and commercializing
RenovoCath®, a novel, FDA-cleared delivery platform, also
announced that three of its abstracts were accepted to be
presented at several upcoming industry conferences, including
ASCO GI 2025. RenovoRx is pioneering a novel therapy
platform called TAMP, which delivers chemotherapy directly to the
tumor through the arterial wall, potentially reducing side effects
and improving treatment effectiveness compared to standard
intravenous therapy. Their ongoing Phase III TIGeR-PaC trial,
evaluating this approach with their FDA-cleared RenovoCath
device, is expected to complete patient enrollment and a key
interim analysis by mid-2025.
"These abstracts support the potential for our TAMP therapy
platform to provide a meaningful advancement in the standard of
care for cancer treatment," said Ramtin
Agah, MD, Chief Medical Officer and Founder of
RenovoRx. "TAMP focuses on drug concentration optimization
in tumors by delivering therapies with our RenovoCath delivery
system. This targeted approach to cancer treatment is designed to
enable physicians to isolate segments of the vascular anatomy
closest to tumors and ensure precise therapeutic delivery, while
potentially minimizing a therapy's toxicities versus the standard
of care. Specifically, our approach enables physicians to utilize
RenovoCath to use pressure to force chemotherapy across the
arterial wall near the tumor site to bathe the target tumor."
Source:
https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/
CONTACT:
USA NEWS
GROUP
info@usanewsgroup.com
(604) 265-2873
DISCLAIMER: Nothing in this publication should be
considered as personalized financial advice. We are not licensed
under securities laws to address your particular financial
situation. No communication by our employees to you should be
deemed as personalized financial advice. Please consult a licensed
financial advisor before making any investment decision. This is a
paid advertisement and is neither an offer nor recommendation to
buy or sell any security. We hold no investment licenses and are
thus neither licensed nor qualified to provide investment advice.
The content in this report or email is not provided to any
individual with a view toward their individual circumstances.
USA News Group is a wholly-owned
subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been
paid a fee for Oncolytics Biotech Inc. advertising and digital
media from the company directly. There may be 3rd parties who may
have shares of Oncolytics Biotech Inc., and may liquidate their
shares which could have a negative effect on the price of the
stock. This compensation constitutes a conflict of interest as to
our ability to remain objective in our communication regarding the
profiled company. Because of this conflict, individuals are
strongly encouraged to not use this publication as the basis for
any investment decision. The owner/operator of MIQ own shares of
Oncolytics Biotech Inc. which were purchased in the open market,
and reserve the right to buy and sell, and will buy and sell shares
of Oncolytics Biotech Inc. at any time without any further notice
commencing immediately and ongoing. We also expect further
compensation as an ongoing digital media effort to increase
visibility for the company, no further notice will be given, but
let this disclaimer serve as notice that all material, including
this article, which is disseminated by MIQ has been approved by
Oncolytics Biotech Inc.; this is a paid advertisement, we currently
own shares of Oncolytics Biotech Inc. and will buy and sell shares
of the company in the open market, or through private placements,
and/or other investment vehicles.
While all information is believed to be reliable, it is not
guaranteed by us to be accurate. Individuals should assume that all
information contained in our newsletter is not trustworthy unless
verified by their own independent research. Also, because events
and circumstances frequently do not occur as expected, there will
likely be differences between the any predictions and actual
results. Always consult a licensed investment professional before
making any investment decision. Be extremely careful, investing in
securities carries a high degree of risk; you may likely lose some
or all of the investment.
Infographic -
https://mma.prnewswire.com/media/2603684/USA_News_Group_Infographic.jpg
Logo
- https://mma.prnewswire.com/media/2603685/5128816/USA_News_Group_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/oncologys-best-minds-set-to-meet-at-upcoming-2025-asco-gastrointestinal-cancers-symposium-302357283.html
SOURCE USA News Group